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Introduction. Hodgkin lymphoma shows a well-known geographic pattern, but temporal changes have been found recently as
well. Patients and Methods. 439 Hodgkin lymphoma patients’ clinicopathological and treatment data were processed in calendar
periods of approximately ten years. The patients were treated at our department from 1980 until the end of 2008. Results. The first
period (1980–89) contained 177 patients, the second (1990–99) 147, and the third (2000–08) 115 Hodgkin lymphoma patients.
The mean age of the patients was 40.1, 35.9, and 36.8 years in order. The male/female ratio: 1.42, 1.45, 1.05 in order. Contrary-
wise a unimodal age group pattern could have been seen with an incidence peak between 30 and 39 in the past decades. The
incidence of classical mixed cellularity histological subtype is decreasing (43.7%, 58.23%, 42.6%, P = 0.0098 (it is only significant
in the second period)); classical nodular sclerosis shows an increasing tendency (25%, 27.32%, 34.78%, P = 0.1734). The first
incidence peak is predominantly created by classical nodular sclerosis, meanwhile the second peak by classical mixed cellularity.
The number of early-stage patients (59.12%) is beyond the advanced stage (40%) in the last decade. Meanwhile, the number of
second-stage patients was increasing (25.8%, 26.35%, 49.56% P < 0.0001) and of patients in third stage was decreasing (53.4 %,
50.67%, 20% P < 0.0001). The 5- and 10-year overall survival data were progressing: 59.7 %, 77.4 %, and 90.5 % and 44.1 %,
70.6 % and 90.5 % (expected survival) in the last decade. Conclusions. Changes can be explained by the altered nature of Hodgkin
lymphoma, the changes in socioeconomic status and the development of diagnostic and therapy methods.
1. Introduction
Our knowledge about Hodgkin lymphoma (HL) is flaring
apace. Nowadays it is obvious that the disease can be divided
into two groups by its pathogenesis and clinical features:
the nodular lymphocyte predominant (NLP) and the classic
subtypes.
Due to the development of diagnostics and the prog-
nosis-based risk-adopted treatment strategies, more than
90% of patients get into complete remission in the developed
countries. The exact etiology of the disease is still unknown,
however, is not uniform since genetic features, viral infec-
tions, and other factors such as diﬀerent lifestyle habits can
contribute to the development of the disease. The role of
the Epstein-Barr virus is obvious. The so-called “two-disease
hypothesis” [1], which proposes that the HL seen in the
younger group is infectious in nature whereas that in the
older persons has causes similar to other types of lym-
phomas. The incidence of HL shows diﬀerences worldwide,
it is more frequent in developed countries, most common in
North America, and less frequent in Asia [2]. Data frommid-
1990s reported an increasing prevalence among young adults
in developing countries and stagnant incidence in western
countries [3]. In the USA from 1974 to 1996, the incidence
of the disease was stagnant among white females, only
decreased among white males; meanwhile, a definite increase
of incidence can be found among black females. Until 1985
an increase after dropping can be found among black males
[4]. As compared to the incidence of HL in the European
Union in 2002 (males: 2.5/100000, females: 1.9/100000), in
Hungary the disease is less frequent among males while is
minimally more frequent among females (males: 2.1/100000,
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Figure 1: The age group pattern of Hodgkin’s lymphoma patients
during the investigated period.
females: 2.1/100000). Among the twenty-five countries of the
European Union (data not known in Romania and Bulgaria),
Hungary is ranked the sixth place in the incidence of the
disease among females and the twenty-second place among
males [5]. In 2002 worldwide, the HL was the most frequent
among males in Yemen, the less frequent in Egypt, and,
additionally, less frequent than the average in Hungary [5].
Earlier epidemiological studies have revealed three pat-
terns of the distribution in HL. Pattern 1, seen in developing
countries and in patients of low socioeconomic status, shows
an early childhood peak and a second peak around the
age of fifty, with tumors predominantly of classical mixed
cellularity (cMC) and classical lymphocyte depletion (cLD)
subtypes with EBV positivity. Pattern 3, seen in developed
countries and in patients of high socioeconomic status,
shows a bimodal age group pattern with a peak incidence
among young adults with tumors mainly of classical nodular
sclerosis (cNS) subtype with EBV negativity. Pattern 2,
seen in countries with transitional economies, has an early
childhood peak and a second (female) decade peak with
equal frequencies of the cMC and cNS subtypes [1, 2].
Considering the socioeconomic changes in Hungary, the
authors regarded them as worthwhile to investigate, whether
the pathological or clinical nature and the treat worth of HL
have changed in the past decades.
2. Patients andMethods
The clinical data of 439 HL patients treated at the University
of Debrecen, Medical and Health Science Center, Institute
for Internal Medicine, 3rd Department of Medicine from
01/01/1980 until the 12/31/2008 were processed in a division
of calendar periods of approximately ten years (first period:
1980–1989, second period: 1990–1999, third period: 2000–
2008).
Identification of histological subtypes was done accord-
ing to Rye’s classification [6], recently according to REAL/
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Figure 2: The pattern of the histological subtypes of Hodgkin’s
lymphoma patients during the investigated period.
WHO classification [7]. Clinical staging was done according
to the Ann Arbor Classification [8] and later with its
Cotswold’s modification [9]. The prognosis of the patients
was given according to the EORTC recommendation [10]
in early stage. In case of advanced-stage patients, prognosis
was given according to the International Prognostic Index
by Hasenclever and Diehl [11]. In advanced-stage disease,
we considered the prognosis to be favourable, when the IPS
value was 0–3, and unfavourable if it was at least 4.
The therapy of the patients occurred due to the current
therapeutic protocols (radiotherapy, chemotherapy, or com-
bined radio- and chemotherapy). Primary polychemother-
apy was dominantly CV(O)PP (cyclophosphamide, vinblas-
tine (vincristine), procarbazine, prednisone) until 1991, then
COPP/ABV (cyclophosphamide, vincristine, procarbazine,
prednisone/adriamycin, bleomycin, vinblastine) from 1991,
recently ABVD (adriamycin, bleomycin, vinblastine, dacar-
bazine) from 1999. Salvage protocols were mainly BEACOPP
(bleomycin, etoposide, adriamycin, cyclophosphamide, vin-
cristine, procarbazine, prednisone), DHAP (dexamethasone,
cytarabin, cisplatin), and CEP (CCNU, etoposide, chloram-
bucil, prednisone). The irradiation consisted of extended-
field, mantle-field, converse Y, (sub)total nodal- or involved-
field radiotherapy—initially with telecobalt machine, then
from 2000 with linear accelerator. High-dose treatment and
autolog hematopoietic stem cell transplantation were also
accessible for treating relapsed or primary resistant patients
from the 1990s [12].
Survival data were analysed using the Kaplan-Meier
method by SPSS15 computer software. For the statistical
analyses the chi2 test was used. P < 0.05 was considered
significant.
3. Results
A total of 439 HL patients were treated primarily during
the investigated period of 29 years. Male- to female-ratio
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Figure 3: (a) The pattern of classical mixed cellularity histological subtype during the investigated period. (b) The pattern of classical nodular
sclerosis histological subtype during the investigated period.
Table 1: The features of Hodgkin’s lymphoma patients during the investigated period.
Period 1980–1989 1990–1999 2000–2008
Number of patients 177 147 115
Male 104 (58.75%) 87 (60%) 59 (51.30%)
Female 73 (41.25%) 60 (40%) 56 (48.70%)
Male/female 1.42 1.45 1.05
Mean age (years)
40.1 35.9 36.8
(11–79) (14–76) (15–74)
Median (years) 38 33 32
B symptoms 92 (51.98%) 75 (51.00%) 59 (51.30%)
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Figure 4: The pattern of the histological subtypes due to sexes
during the investigated period.
decreased to 1.05 recently, instead of male predominance
until now. The mean and median age was decreasing
(Table 1).
Investigating the age of the patients, the age group
pattern of the first period is unimodal, with one incidence
peak between 30 and 39 years of age. We found a bimodal
age group pattern in the second and third periods. The first
incidence peak of this pattern can be found between 20 and
29 (like nowadays), the second peak between 40 and 49 in
the second period, and between 50 and 59 in the third period
(Figure 1).
The number of HL patients with classic mixed cellu-
larity histological subtype was decreasing after a temporary
increase (43.7%, 58.23%, 42.6%, P = 0.0098 (it is only sig-
nificant in the second period)). The classic nodular sclerosis
subtype shows a increasing tendency (25%, 27.32%, 34.78%,
P = 0.1734). Classical lymphocyte predominant subtype
(cLP) was decreasing (17.1%, 7.57%, 5.21%, P = 0.0038).
The number of classical lymphocyte depletion (cLD) subtype
was decreasing significantly also (14.2%, 6.19%, 6.06%,
P = 0.0181), nodular lymphocyte predominant (NLP)
histological subtype can be seen only in the past decade,
when the REAL/WHO classification was used (Figure 2).
We found that the first incidence peak of the age group
pattern is created predominantly by cNS; meanwhile, the
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Figure 5: The distribution of the stages during the investigated period.
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Figure 6: Overall survival during the investigated period.
second incidence peak is created by cMC histological subtype
(Figures 3(a) and 3(b)).
Investigating the histological subtypes according to the
sexual distribution, we found that cMC subtype is predom-
inant among males in every period, its ratio is much lower
among females, and in the third period cNS subtype became
predominant. Among males the cMC subtype, meanwhile
among females the cNS subtype, is the most common in
the third period. The incidence of cLP and cLD subtypes
decreased; cLD shows a slight increase in the third period
again. Furthermore, NLP subtypes have been diagnosed in
the last periods with an incidence of 6.08% (Figure 4).
Comparing the early- (first-second) and advanced-
(third-fourth) stage disease, we found an increased ratio of
early-stage disease, and the diﬀerence was statistically signifi-
cant. The increase comes on one hand from the significant
growth of the number of second stage patients (25.8%,
26.35%, 49.56%, P < 0.0001) and on the other hand from the
significant reduction of the number of third stage patients
(53.4%, 50.67%, 20%, P < 0.0001). Nowadays half of the
patients is diagnosed in the second stage of the disease
(Figure 5).
From the first symptom (lymphadenomegaly and/or
complain) until the diagnosis of the disease lasted an average
6.2 months in the first period. In the second period this only
took 4.2 months and only 2.6 months in the third period.
We found that 45.59% of the early-stage patients and
28.26% of the advanced-stage patients were concerned to be
in the unfavourable prognostic group.
The majority of the patients had B symptoms at the time
of the diagnosis.
The 5-year overall survival was 59.7%, 77.4%, and re-
cently 90.5% (P < 0.001), and the 10-year overall sur-
vival data were also progressing: 44.1%, 70.6% and 90.5%
(prognosed survival) in the last decade (Figure 6).
During the investigated period, a total number of
154 patients passed away. More than 60% of them were
diagnosed in the first period; they died predominantly of
Hodgkin’s lymphoma. The mortality coming from the basic
disease was decreasing after this time (in the second period
the basic disease mortality reduced into half), the remaining
patients died of infection, second tumor, cardiopulmonary
failure, and other factors (e.g., accidents) in nearly the
same ratio. Comparing to the others, in the last period the
mortality becameminimal with still the predominance of the
basic disease (Figure 7).
4. Conclusion
The incidence of HL was the greatest in North America
(male: 3.2/100000, female: 2.4/100000), the smallest in East
Asia (male: 0.3/100000, female: 0.1/100000), in Central and
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Figure 7: The distribution of the cause of death, HL: Hodgkin lymphoma, LFU: lost to followup.
Eastern Europe ??? both males and females: 2.3/100000 in
2002 [2]. Data of Hungary from 2000 to 2003 reports
an average incidence of 2.02/100000 among males and
1.59/100000 among females, but estimating Hungarian data,
the fact must be considered that probably not every case
was reported. Hence, the incidence of the disease can be
considered average, both on the whole and due to sexual
distribution [20]. Our current trial is not representative;
hence, estimating incidence is not possible.
In Hungary 9 trials dealed with data of HL patients
(Table 2). The duration of these trials diﬀers significantly
from each other (1 year [14] to 22 years [13, 19]); further-
more, these trials show great variability due to geographic
diﬀerences (data from whole Hungary [14, 20] to investigate
patients from only one county [13, 15]). Hence, exacting
comparison and drawing conclusions is not possible, and
attention can be attracted to further comprehensive trials.
Investigating sexual distribution generally male predom-
inance was found; three trials found slight female predomi-
nance [12, 14, 15]. This ratio came from the female predom-
inance in the cNS subtype in Kele´nyi et al. Estimating the
results of Iva´nyi et al. is hard, because among the diagnosed
86 patients only 66 patients’ data were processed during
their investigated period [15]. The mean age is around 40
in every trial (35.8–41.7 years) and shows a persistent slight
decrease. The most common histological subtype—except
for one trial—was cMC. Ille´s et al. presented countrywise
data, whereas cNS was found to be the most common
subtype during the investigated period of 4 years (between
2000 and 2003). Both uni- and bimodal age group patterns
were found; the incidence peak in young adults around
twenties was present everywhere. B symptoms were present
unequivocally, more than half of the patients in every
trial. The majority of the patients were diagnosed in the
advanced stage, but it is hope worthy that both a trial in
the current decade (2000–2003 countrywise data [20]) and
our investigation’s last period reports the diagnosis in early
stage.
Between 1960 and 1997 in Scandinavian countries, in
India, and in North America, the increase of the incidence
of HL was found among teenagers and young adults.
This increase was found rather among females and was
primarily linked to the cNS subtype. In elderly rather a
decreasing tendency was found, which was explained by the
development of diagnostical methods [21]. A trial between
1984 and 1993 in the United Kingdom found the decrease of
the incidence in both sexes, in every age groups, except for
males between 1 and 24 [22]. Investigating seven European
countries no changes was found in the incidence between
1985 and 1992 [23].
In our current study, the authors found the decrease of
the number of patients, although the last period was one year
shorter. The male/female ratio decreased as well, currently
the number of male and female patients is almost equal. The
mean age shows a decreasing tendency as well. Although the
reason of this phenomenon is unknown, but shows similarity
to the mentioned international data above [21].
Whereas we found a unimodal age group pattern in the
first two periods, nowadays a bimodal age group pattern
can be seen, with an incidence peak in young adults (20–
29 years) and another in elderly (50–59 years), likewise to
developed countries [2]. The fact that not all patients—
especially the elderly—were treated in oncohematological
centers can play a role in the explanation of the previously
observed unimodal age group pattern. Hence, reporting the
disease to the Hungarian Hodgkin’s Disease Work Group did
not occur every time. This phenomenon matches with the
results of the last Hungarian survey [20].
Correspondingly, the distribution of the histological sub-
types is characteristic to the developed countries. We found
the significant decrease of the cMC subtype and the increase
of the cNS subtype (not significantly). In the last period the
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Table 2: Hungarian trials dealing with HL patients.
Author
Investigated
period
Number
of HL
patients
Male/female
ratio
Mean ages
(years)
Most
common
histological
subtype
(%)
Age group
pattern
B symptoms
(%)
Early stages
(%)
Advanced
stages (%)
Istva´n and
Giczy, 1979
[13]
1953–1974 166 1.81 : 1 Unknown Unknown
Bimodal
(15–40 and
50–65 years)
Unknown Unknown Unknown
Kele´nyi and
Va´rbiro´, 1980
[14]
1978 69 0.97 : 1 41.7 MC 45%
Bimodal
(20–30 and
50–70 years)
Unknown Unknown Unknown
Iva´nyi et al.,
1988 [15]
1975–1986 66 0.88 : 1 35.8 MC 36.36% Unknown 54.54% 34.80% 65.20%
Fleischmann,
1985 [16]
1978–1985 167 Unknown Unknown Unknown Unknown 60% 16.90% 83.10%
Bere´nyi et al.,
1989 [17]
1983–1987 233 1.53 : 1 Unknown MC 43.8%
Bimodal
(10–20 and
40–60 years)
56.70% 41.60% 58.40%
Endre´di et al.,
1991[18]
1987–1988 202 1.15 : 1 39.5 MC 42.6% Unknown Unknown Unknown Unknown
Ille´s et al., 1998
[19]
1975–1997 473 1.46 : 1 Unknown MC 43.2%
Unimodal
(20–30 years)
53.30% 33.30% 66.70%
Ille´s et al., 2004
[20]
2000–2003 611 1.27 : 1 39.6 NS 44%
Unimodal
(20–30 years)
51.00% 66.00% 34.00%
Simon et al.,
2007 [12]
1995–2004 163 0.96 : 1 36 MC 48.5%
Bimodal
(20–30 and
50–60 years)
51.00% 41.10% 58.90%
Milte´nyi, Ille´s
et al., 2008
1980–1989 177 1.42 : 1 40.1 MC 43.7%
Unimodal
(30–40 years)
51.60% 33% 67%
Milte´nyi, Ille´s
et al., 2008
1990–1999 147 1.45 : 1 35.9 MC 58.23%
Bimodal
(20–30 and
40-50 years)
50.90% 31% 69%
Milte´nyi, Ille´s
et al., 2008
2000–2008 115 1.04 : 1 36.8 MC 42.6%
Bimodal
(20–30 and
50–60 years)
50.80% 59.12% 40%
incidence peak of young adults is created by the cNS subtype;
meanwhile, the other incidence peak among elderly is created
by the cMC subtype. Due to the introduction of the WHO’s
histological classification since 2000, the number of patients
with cLP subtype decreased and with the new subtype, the
NLP increased.
Patients diagnosed in the early stage become more freq-
uent in the last period. The number of patients in the
advanced stage decreased significantly, parallel with the
significant increase of early-stage patients. Nowadays every
second patient is diagnosed in stage two In the last decades
the number of patients in stage three was decreasing contin-
uously; accordingly, the number of stage two and early-stage
patients were increasing continuously. This tendency suits
with international authors’ observation [24, 25]. Beyond
the developing diagnostic methods (immunohistochemi-
cal examinations, developing imaging methods, like using
PET/CT routinely), the patients’ awareness (thanks to media,
internet) and the highly educated workers in basic medical
attendance can also play a role in the backstage of this
phenomenon. Hence, the patients are treated earlier. Since,
the patients are diagnosed in earlier stages, their chance to
survive and their quality of life are continuously progressing,
because of the lower dose and less toxic treatment at their
case. Accordingly, the overall survive progressed.
According to international data, the 10-year overall sur-
vival of HL patients is 75–85% [20, 26], which are similar
to our results. 5-year overall survival progressed, because
of better treatment based on prognostic factors and better
supportation.
The decrease of mortality—especially the mortality
because of the basic disease—can be explained by developing
treating methods as well. The mortality because of the
basic disease fall to the half between the first and the
second periods and fall to the third between second and
third periods. Due to the more toxic polichemotherapy and
extended-field, greater-dose irradiation used in the previous
periods, the mortality coming from the late side eﬀects of
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the treatment is still determinative. Only further follow can
decide, whether how much can new treatment methods
reduce these factors of mortality.
Investigating HL patients in the same geographical
localisation in diﬀerent periods gives an opportunity to
observe the eﬀects of diﬀerent factors (e.g., viral infection,
socioeconomic changes) on the characteristics of the disease
[1]. Based on our results, it can be established that the clinical
pathological features of Hodgkin lymphoma are changing in
Hungary. We found the pattern to be characteristic to the
developed countries out of the three epidemiologic patterns.
Rising economy aﬀects the socioeconomic status. The popu-
lation is infected (e.g., EBV) fewer times. Beside the changes
of these immunological features, much more environmental
expositions aﬀect people than previously stated. These facts
and comprehensive (countrywise or diﬀerent geographical
locations) epidemiological trials can help in questing for the
reasons, the treatment, and the survival of the disease.
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